22 citations
,
April 1998 in “Dermatologic Clinics” This article reviews the therapeutic use of interferons and other cytokines in various viral, tumorous, and inflammatory diseases, discussing their biological effects and potential future applications without presenting new experimental results.
209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.
278 citations
,
March 2013 in “Gut” In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.
71 citations
,
May 2024 in “New England Journal of Medicine” This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.
60 citations
,
September 2004 in “Pediatric Dermatology” In this study, a 10-year-old girl developed vitiligo and psoriasis during IFN-alfa treatment for chronic hepatitis B, with neither condition improving after stopping the therapy.
24 citations
,
April 2013 in “PLOS ONE” This study identifies substance P, TNFα, and IFNγ as novel regulators of prolactin and its receptor expression in human skin, suggesting intracutaneous prolactin is not controlled by dopamine.
14 citations
,
January 2006 in “Skinmed” A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.
9 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” This study found that cutaneous ulcers caused by interferon are not associated with the medication's dosage.
6 citations
,
October 2016 in “Journal of Chemotherapy” This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.
July 2025 in “International Journal of Trichology” This review investigates how various intrinsic factors—such as growth factors, cytokines, chemokines, and interferons—regulate hair growth through evidence gathered from in vitro and in vivo studies, highlighting the need for further research in human subjects to validate these findings.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that in alopecia areata, epidermal γδ T cells and macrophages contribute to the disease alongside CD8 T cells, with the expression of BST2 marking interferon-driven immune activation in both mouse and human skin, which decreases following treatment with the JAK inhibitor tofacitinib.
June 2023 in “jurnal veteriner” In this study, Typhonium flagelliforme leaf-ethanolic extract combined with natural interferon was observed to stabilize body weight, inhibit tumor growth, and reduce mitosis, angiogenesis, and certain protein expressions in carcinogen-induced tumors in female mice, suggesting potential antitumor effects.
107 citations
,
December 2003 in “Dermatologic Therapy” This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.
2 citations
,
March 2015 in “Hepatitis Monthly” This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.
64 citations
,
January 2009 in “Canadian Journal of Gastroenterology” This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.
47 citations
,
December 2011 in “Experimental Dermatology” This study suggests that the neuropeptide CGRP may protect against, but not restore, IFNγ-induced collapse of hair follicle immune privilege in alopecia areata.
45 citations
,
October 2009 in “Dermatology” This study observed that long-term recombinant interferon alpha-2b therapy was associated with considerable hair loss in some patients, indicated by a telogen effluvium pattern on trichograms.
41 citations
,
August 2007 in “European Journal of Gastroenterology & Hepatology” This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.
36 citations
,
January 1993 in “Gut” In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.
35 citations
,
January 2002 in “Dermatology” This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.
34 citations
,
April 2008 in “Journal of the European Academy of Dermatology and Venereology” This study reported that while lichen planus was not significantly linked to hepatitis C virus infection, pruritus, dry skin, and hair loss were more common in HCV patients post-interferon treatment.
27 citations
,
April 2005 in “Journal of Chemotherapy” This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.
26 citations
,
June 2005 in “Journal of The American Academy of Dermatology” In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.
20 citations
,
September 2003 in “Journal of Investigative Dermatology” Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.
17 citations
,
January 2011 in “The Korean Journal of Hepatology” This case report details an occurrence of Vogt-Koyanagi-Harada disease during pegylated interferon-α2b and ribavirin therapy for chronic hepatitis C.
16 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that intramuscular anti-IFN-γ significantly stabilized and promoted hair regrowth in alopecia areata patients with patchy, progressive hair loss, whereas those with total baldness showed more limited improvement.
13 citations
,
December 2006 in “Journal of experimental animal science” This study found that injecting interferon gamma into C3H/HeJ mice did not alter the frequency or onset of alopecia areata, suggesting the protein alone does not trigger the disease.
13 citations
,
January 2002 in “Biochemical and biophysical research communications” This study observed that interferon β secreted by dermal papilla cells may negatively regulate the growth of outer root sheath cells in hair follicles.
11 citations
,
April 2014 in “Journal of Clinical Virology” This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.
10 citations
,
September 2014 in “European Journal of Dermatology” This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.